Emerging Infectious Diseases
FDA approves vaccine for chikungunya
The U.S. Food and Drug Administration (FDA) recently approved a single-dose chikungunya vaccine developed by Denmark-based Bavarian Nordic A/S, a global vaccine company, for people age 12 years and older. Chikungunya is a mosquito-borne disease caused by the chikungunya virus. The virus has been... Read More »
Senators raise concerns about proposed global pandemic accord for its weakening of IP protections
In a letter to United States National Security Advisor Jake Sullivan, a group of senators voiced concern over a proposed global accord by the World Health Organization (WHO) that seeks to aid pandemic prevention, preparedness, and response. However, the lawmakers argued that it could also weaken... Read More »
Infectious Diseases Society of America awards excellence designation to 14 institutions
A total of 14 organizations earned the Infectious Diseases Society of America’s (IDSA) Antimicrobial Stewardship Centers of Excellence designation last week, for programs advancing science to better fight antimicrobial resistance. The program emphasized these institutions’ abilities to... Read More »
FDA approves world’s first Chikungunya vaccine
Valneva SE won approval for the world’s first Chikungunya vaccine – IXCHIQ – last week from the U.S. Food and Drug Administration (FDA). It is a major milestone for a viral disease that has plagued humanity for decades, thanks to the bites of mosquito carriers. Although originally found... Read More »
Bill to ensure mass production of medical countermeasures greenlit by House Energy and Commerce Health Subcommittee
In a vote from the House Energy and Commerce Subcommittee on Health, U.S. Rep. Bob Latta’s (R-OH) Helping Evaluate Appropriate Logistical Infrastructure for National Government (HEALING) Response Act (H.R. 3703) was cleared as part of a broader reauthorization legislation. Latta’s bill, as... Read More »
Bipartisan Disease X Act would push future pandemic response through countermeasures program
While some have started to put the COVID-19 pandemic firmly behind them, other emphasize the lessons learned, and two of those figures this week introduced the Senate Disease X Act of 2023, proposing creation of a federal Disease X Medical Countermeasures program. Meant to ready the nation for... Read More »
Major collaborative study shows preparedness made largest difference in COVID-19 pandemic
Nations with the best capacity to prevent, detect and respond to disease threats weathered the COVID-19 pandemic with lower overall mortality rates than less prepared nations, according to a new study from partners at the Brown University School of Public Health, Bill & Melinda Gates Foundation and... Read More »
New DARPA program targets bloodstream infections
Defense Advanced Research Projects Agency (DARPA) officials are touting a new program they maintain addresses bloodstream infections (BSI)-causing fungal and bacterial pathogens. The Synthetic Hemo-technologIEs that Locate & Disinfect (SHIELD) program seeks to develop broad, preventive... Read More »
Senate HELP Committee seeks feedback on proposal to reauthorize public health emergency preparations
Members of the Senate Health, Education, Labor, and Pensions (HELP) Committee released a discussion draft of a reauthorization for the Pandemic and All-Hazards Preparedness Act (PAHPA), in search of feedback. PAHPA, first created in 2006, established the Assistant Secretary for Preparedness and... Read More »
World needs swift action if it is to ready itself for next pandemic, international security organizations say
A digital report released last week by the Nuclear Threat Initiative (NTI) | bio and the Munich Security Conference (MSC) sounded the alarm in advance of the world’s next pandemic, warning that without bold action, catastrophe will likely follow. Simply put: the world is not ready, by their... Read More »
New funding opportunity seeks network for disease forecasting at CDC
Under a Notice of Funding Opportunity (NOFO) launched last week, the Center for Forecasting and Outbreak Analytics (CFA) announced efforts to strengthen outbreak response among decision makers through creation of a disease forecasting network. CFA is a part of the Centers for Disease Control... Read More »
Republican legislators eye punishments abroad following FBI, DOE determinations of COVID-19 lab leak origins
Moving quickly in the wake of new determinations about the potential origins of the COVID-19 pandemic, U.S. Rep. Randy Feenstra (R-IA) last week introduced legislation to punish foreign countries found to conduct chemical and biological experiments that threaten public health and global security.... Read More »
NIH scientists advance understanding of mpox through development of mouse model
According to new research published in “Proceedings of the National Academy of Science,” scientists from the National Institute of Allergy and Infectious Diseases (NIAID) have developed a mouse model of the mpox virus (MPXV) as a way to demonstrate and understand aspects of its... Read More »
EBOV-based experimental Sudan virus vaccine shows promise among macaques
In use on macaques, at least, an experimental Sudan virus (SUDV) vaccine created by a National Institutes of Health (NIH) research group recently provided complete protection against a lethal case of SUDV. According to findings published in The Lancet Microbe, the vaccine candidate – VSV-SUDV... Read More »
Marburg vaccine candidate deemed safe and effective in small, first-in-human study
According to results published in The Lancet this week, a Phase 1, first-in-human test of an experimental Marburg virus vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID), good safety profiles and an active immune response brought hope for the candidate’s... Read More »
GAO calls for greater oversight of HHS research involving pandemic-capable pathogens
As called for under the CARES Act stimulus bill of 2020, the Government Accountability Office (GAO) conducted an investigation of the U.S. Department of Health and Human Services’ (HHS) oversight practices surrounding research into pandemic pathogens and found cause for concern. While such... Read More »
End of year government funding bill included public health measures from PREVENT Pandemics Act
As lawmakers process the passage of the government funding bill at the tail end of December 2022, U.S. Sen. Susan Collins (R-ME) announced that major portions of the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act) were included in its... Read More »
WHO, CDC declare Ugandan Ebola outbreak over
It was the worst Ebola outbreak Uganda had experienced in decades, but after 42 days – or two incubation periods – since the last case was reported, the World Health Organization (WHO), Uganda, and the Centers for Disease Control and Prevention (CDC) have declared the viral threat over. “I... Read More »
National Institutes of Health touts Home Test to Treat program
The National Institutes of Health (NIH) is touting the new Home Test to Treat program, a virtual community health intervention that provides free COVID-19 health services and treatments in selected communities. “At-home testing for COVID-19 is now widely available in the United States, as are... Read More »
CDC sticks COVID-19 test requirements on air passengers from China
Even as China reopens itself to travel following years of heavy restriction due to the COVID-19 pandemic, its citizens face a new roadblock from entry to the United States: a demand for negative COVID-19 tests for any flier. The restriction was announced by the Centers for Disease Control and... Read More »
HHS expands Tamiflu access for flu season
With flu season in full swing, the U.S. Department of Health and Human Services (HHS) announced this week that additional supplies of Tamiflu would be tapped to meet increased demand. Jurisdictions will manage any Tamiflu requests through the Strategic National Stockpile (SNS) in collaboration... Read More »
Randomized trials of three Ebola vaccine strategies for adults, children dub regimens safe
In two randomized, placebo-controlled trials of three Ebola vaccine administration regimens for adults and children, the Partnership for Research on Ebola Vaccination (PREVAC) recently published results concluding that all regimens were safe and effective. Vaccine candidates included Ad26.ZEBOV,... Read More »
NIH identifies new funding in support of Valley Fever vaccine research, development
Following up on a National Institute of Allergy and Infectious Diseases (NIAID) Notice of Special Interest from November that sought support for research into a Valley Fever vaccine, the National Institutes of Health (NIH) recently announced that additional funding avenues have been... Read More »
New Senate report criticizes significant failures in initial federal COVID-19 response, pandemic preparedness
Following a two-year investigation by U.S. Sen. Gary Peters (D-MI), chairman of the Senate Homeland Security and Governmental Affairs Committee, a new report detailed significant failures in the federal government’s initial response to the COVID-19 pandemic and overall preparedness. Released... Read More »
CEPI extends VBI Vaccines partnership for development of multivalent coronavirus vaccine
A partnership between VBI Vaccines Inc. and the Coalition for Epidemic Preparedness Innovations (CEPI) expanded this week with a new development agreement seeking the development of multivalent coronavirus shots for use against multiple coronavirus threats. Based on VBI’s proprietary enveloped... Read More »
NIAID awards more than $12M for development of antiviral therapeutics
As part of its Antiviral Program for Pandemics (APP), meant to accelerate the discovery, development, and manufacturing of antivirals, the National Institute of Allergy and Infectious Diseases (NIAID) recently awarded more than $12 million to three institutions for new therapies. These new... Read More »
First look at global vaccine market since COVID-19 shows development still lagging due to profit-over-health mindset
Capitalistic values continue to hinder vaccine development, according to the World Health Organization’s (WHO) first report on the global vaccine market since COVID-19, with prioritizes vaccines not being developed due to limited profit potential and limited access for lower-income countries... Read More »
Clinical data shows Pfizer, BioNTech Omicron BA.4/BA.5 booster offers higher protection in adults
Pfizer and BioNTech announced updates from a Phase 2/3 clinical trial of their bivalent booster for the COVID-19 variants Omicron BA.4/BA.5 last week, pointing to the 4-fold higher emergence of neutralizing antibody titers among treated adults older than 55, comparative to the original COVID-19... Read More »
BARDA invites Soligenix to submit contract proposal for thermostabilized Sudan Ebola, Marburg virus vaccines
Biopharmaceutical company Soligenix, Inc. recently received an invitation from the Biomedical Advanced Research and Development Authority (BARDA) to submit a contract proposal for millions of dollars in development support for single vial, thermostabilized subunit vaccines for the Sudan ebolavirus... Read More »
CEPI, SK bioscience collaboration seeks to address rapid Disease X response
Coalition for Epidemic Preparedness Innovations (CEPI) and SK bioscience personnel are touting a collaboration to facilitate rapid response to unknown pathogens with epidemic and pandemic potential or Disease X. The partnership agreement, in which CEPI is slated to provide up to $40 million in... Read More »
Merck, Bill & Melinda Gates Medical Research Institute to develop two tuberculosis antibiotics
Through a new licensing agreement between Merck and the Bill & Melinda Gates Medical Research Institute, two preclinical antibacterial candidates will be developed and evaluated for potential use in the treatment of tuberculosis (TB). “Tuberculosis is one of the world’s most significant... Read More »
BARDA, BioFire Defense partner on new molecular panel to test human coronaviruses
A new partnership united BioFire Defense, LLC, and the U.S. Biomedical Advanced Research and Development Authority (BARDA) last week under a contract to develop a pan-coronavirus test panel for known, novel, and emerging human coronaviruses. This panel, known as the BioFire Emerging CoV Panel,... Read More »
NIAID partners with Democratic Republic of the Congo for new trial of monkeypox antiviral TPOXX
Together, the Democratic Republic of the Congo (DRC) National Institute for Biomedical Research (INRB) and the United States National Institute of Allergy and Infectious Diseases (NIAID) are co-leading an evaluation trial of TPOXX, an antiviral drug for monkeypox. With this year’s worldwide... Read More »
BARDA, DIazyme Laboratories developing rapid test to measure neutralizing SARS-CoV-2 antibodies
Through a new partnership with Diazyme Laboratories, Inc., the Biomedical Advanced Research and Development Authority (BARDA) announced this week that efforts are underway to develop a fast, high-throughput, fully automated test to detect SARS-CoV-2 neutralizing antibodies. The focus is on... Read More »